Harmony Biosciences Holdings, Inc. (HRMY): Revenue
$868.45M
Year ended 2025-12-31
$959.90M
Trailing 12 months to 2026-06-30
+25.6%
3-year compound annual growth
+40.3%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $868.45M | +21.5% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $714.73M | +22.8% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $582.02M | +32.9% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $437.86M | +43.4% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $305.44M | +91.2% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $159.74M | n/m | 2023-02-21, From 2020-01-01 |
| 2019-12-31 | $6.00M | n/a | 2022-02-28, From 2019-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $868.45M | +21.5% |
| ANI Pharmaceuticals Inc (ANIP) | 2025-12-31 | $883.37M | +43.8% |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 2025-09-30 | $829.45M | n/m |
| Ionis Pharmaceuticals Inc (IONS) | 2025-12-31 | $943.71M | +33.8% |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2025-12-31 | $958.40M | +432.1% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $780.57M | +23.6% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $761.41M | +12.8% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $742.90M | -28.8% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $726.41M | +3.6% |
Compare HRMY, ANIP, ARWR, IONS side by side · Screen every company in Pharmaceutical Preparations ↗